Enliven Therapeutics Company Leadership
| ELVN Stock | 21.08 0.16 0.76% |
Enliven Therapeutics' insiders are aggressively selling. The analysis of insiders' sentiment of trading Enliven Therapeutics stock suggests that virtually all insiders are panicking at this time. Enliven Therapeutics employs about 62 people. The company is managed by 6 executives with a total tenure of roughly 145 years, averaging almost 24.0 years of service per executive, having 10.33 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-03-17 | Samuel Kintz | Disposed 12500 @ 20.83 | View | ||
| 2025-03-07 | Anish Patel | Disposed 6667 @ 21.44 | View | ||
| 2025-02-27 | Benjamin Hohl | Disposed 3250 @ 20.41 | View | ||
| 2025-02-07 | Anish Patel | Disposed 6667 @ 21.93 | View | ||
| 2025-02-05 | Benjamin Hohl | Disposed 1000 @ 22.52 | View | ||
| 2025-01-27 | Benjamin Hohl | Disposed 3250 @ 21.59 | View | ||
| 2025-01-07 | Anish Patel | Disposed 21700 @ 24.18 | View | ||
| 2025-01-03 | Benjamin Hohl | Disposed 1000 @ 25.04 | View | ||
| 2024-12-30 | Benjamin Hohl | Disposed 900 @ 22.51 | View | ||
| 2024-12-27 | Benjamin Hohl | Disposed 3350 @ 22.15 | View | ||
| 2024-11-27 | Benjamin Hohl | Disposed 5250 @ 24.89 | View | ||
| 2024-10-28 | Benjamin Hohl | Disposed 6250 @ 28.56 | View | ||
| 2024-10-18 | Samuel Kintz | Disposed 924 @ 30 | View | ||
| 2024-10-15 | Richard A Heyman | Disposed 1270 @ 27.67 | View | ||
| 2024-10-09 | Samuel Kintz | Disposed 16710 @ 28.15 | View |
Monitoring Enliven Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Enliven |
Enliven Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2187) % which means that it has lost $0.2187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3204) %, meaning that it created substantial loss on money invested by shareholders. Enliven Therapeutics' management efficiency ratios could be used to measure how well Enliven Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of March 2025, Return On Tangible Assets is likely to drop to -0.29. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, Enliven Therapeutics' Total Assets are very stable compared to the past year. As of the 23rd of March 2025, Total Current Assets is likely to grow to about 334 M, while Other Current Assets are likely to drop about 3.2 M.As of the 23rd of March 2025, Common Stock Shares Outstanding is likely to grow to about 49.4 M, while Net Loss is likely to drop (23.4 M).
Enliven Therapeutics Workforce Comparison
Enliven Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,461. Enliven Therapeutics holds roughly 62.0 in number of employees claiming about 4% of equities under Health Care industry.
Enliven Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enliven Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enliven Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Enliven Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enliven Therapeutics Notable Stakeholders
An Enliven Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Enliven Therapeutics often face trade-offs trying to please all of them. Enliven Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Enliven Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joseph Lyssikatos | CoFounder Officer | Profile | |
| Samuel MBA | CEO, CoFounder | Profile | |
| Benjamin Hohl | CFO Development | Profile | |
| Anish PharmD | CoFounder COO | Profile | |
| Helen MD | Chief Officer | Profile | |
| Dr Esq | Chief Development | Profile |
About Enliven Therapeutics Management Performance
The success or failure of an entity such as Enliven Therapeutics often depends on how effective the management is. Enliven Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Enliven management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Enliven management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.34) | (0.35) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.29) | (0.27) |
Enliven Therapeutics Workforce Analysis
Traditionally, organizations such as Enliven Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Enliven Therapeutics within its industry.Enliven Therapeutics Manpower Efficiency
Return on Enliven Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 14.8M | |
| Working Capital Per Employee | 4.9M | |
| Working Capital Per Executive | 50.4M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.